



## **Exelixis Announces February 10 Webcast of Presentation at the 11th Annual BIO CEO & Investor Conference**

February 5, 2009

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, the company's Executive Vice President and Chief Financial Officer, will present at the 11<sup>th</sup> Annual BIO CEO & Investor Conference at 2:45 p.m. EST/11:45 a.m. PST on Tuesday, February 10, 2009. Mr. Karbe will discuss the company's development pipeline and corporate strategy.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at [www.exelixis.com](http://www.exelixis.com).

### **About Exelixis**

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at [www.exelixis.com](http://www.exelixis.com).

*Exelixis and the Exelixis logo are registered U.S. trademarks.*

Source: Exelixis, Inc.

Exelixis, Inc.

Charles Butler, 650-837-7277 (Investors)

Senior Director

Corporate Communications

& Investor Relations

[cbutler@exelixis.com](mailto:cbutler@exelixis.com)

Soleil Maxwell Harrison, 650-837-7012 (Media)

Senior Manager

Corporate Communications

[sharrison@exelixis.com](mailto:sharrison@exelixis.com)